Scorpius Holdings Commends the U.S. House of Representatives’ Passage of the BIOSECURE Act
Scorpius Holdings (NYSE American: SCPX) commends the U.S. House of Representatives for passing the BIOSECURE Act with strong bipartisan support (306-81 vote). This legislation aims to secure America's pharmaceutical supply chain, strengthen national biosecurity, and improve preparedness for public health emergencies. The Act restricts U.S. Government-funded drug developers from contracting with select China-based biomanufacturing companies, potentially increasing demand for domestic production capabilities.
Scorpius CEO Jeff Wolf anticipates significant opportunities to expand the company's project pipeline as a result of this legislation. As a U.S.-based integrated contract development and manufacturing organization (CDMO), Scorpius is positioned to support biopharmaceutical companies navigating these changes with its cutting-edge expertise and modern facilities.
Scorpius Holdings (NYSE American: SCPX) elogia la Camera dei Rappresentanti degli Stati Uniti per aver approvato il BIOSECURE Act con un forte sostegno bipartisan (voto 306-81). Questa legislazione mira a garantire la sicurezza della catena di fornitura farmaceutica americana, rafforzare la biosecurity nazionale e migliorare la preparazione per le emergenze sanitarie pubbliche. La legge limita i produttori di farmaci finanziati dal governo degli Stati Uniti dal contrattare con alcune aziende di biomanifattura con sede in Cina, aumentando così la domanda per le capacità di produzione domestica.
Il CEO di Scorpius, Jeff Wolf, si aspetta opportunità significative per espandere il pipeline di progetti dell'azienda grazie a questa legislazione. In qualità di organizzazione integrata di sviluppo e produzione su contratto (CDMO) con sede negli Stati Uniti, Scorpius è ben posizionata per supportare le aziende biotecnologiche che affrontano questi cambiamenti, grazie alla sua expertise all'avanguardia e alle strutture moderne.
Scorpius Holdings (NYSE American: SCPX) felicita a la Cámara de Representantes de EE.UU. por aprobar el BIOSECURE Act con un fuerte apoyo bipartidista (voto de 306-81). Esta legislación tiene como objetivo asegurar la cadena de suministro farmacéutico de América, fortalecer la bioseguridad nacional y mejorar la preparación para emergencias de salud pública. La ley restringe a los desarrolladores de medicamentos financiados por el gobierno de EE.UU. de contratar con ciertas empresas de biomanufactura con sede en China, lo que potencialmente aumenta la demanda de capacidades de producción nacional.
El CEO de Scorpius, Jeff Wolf, anticipa oportunidades significativas para expandir el pipeline de proyectos de la empresa como resultado de esta legislación. Como organización integrada de desarrollo y fabricación por contrato (CDMO) con base en EE.UU., Scorpius está posicionada para apoyar a las empresas biofarmacéuticas que navegan por estos cambios con su experiencia de vanguardia y modernas instalaciones.
스코르피우스 홀딩스 (NYSE American: SCPX)는 미국 하원이 BIOSECURE Act를 강력한 초당적 지지(306-81 투표)로 통과시킨 것을 칭찬합니다. 이 법안은 미국의 제약 공급망을 확보하고 국가 생물안보를 강화하며 공공 보건 비상 사태에 대한 준비 태세를 개선하는 것을 목표로 합니다. 이 법안은 미국 정부 자금을 지원받는 의약품 개발자가 특정 중국 기반 생물 제조 회사와 계약하는 것을 제한하여 국내 생산 능력에 대한 수요를 증가시킬 가능성이 있습니다.
스코르피우스의 CEO 제프 울프는 이 법안의 결과로 회사의 프로젝트 파이프라인을 확장할 수 있는 중요한 기회를 기대하고 있습니다. 미국에 본사를 두고 있는 통합 계약 개발 및 제조 조직(CDMO)인 스코르피우스는 이러한 변화를 네비게이션할 때 생물 제약 회사들을 지원할 수 있는 최첨단 전문성과 현대적인 시설을 갖추고 있습니다.
Scorpius Holdings (NYSE American: SCPX) félicite la Chambre des représentants des États-Unis pour avoir adopté le BIOSECURE Act avec un fort soutien bipartisan (vote de 306-81). Cette législation vise à sécuriser la chaîne d'approvisionnement pharmaceutique américaine, à renforcer la biosécurité nationale et à améliorer la préparation aux urgences de santé publique. La loi limite les développeurs de médicaments financés par le gouvernement américain à contracter avec certaines entreprises de biomanufacture basées en Chine, ce qui pourrait augmenter la demande de capacités de production nationales.
Le PDG de Scorpius, Jeff Wolf, anticipe d'importantes opportunités d'élargir le pipeline de projets de l'entreprise grâce à cette législation. En tant qu'organisation intégrée de développement et de fabrication sous contrat (CDMO) basée aux États-Unis, Scorpius est bien positionnée pour soutenir les entreprises biopharmaceutiques qui font face à ces changements, avec son expertise à la pointe et ses installations modernes.
Scorpius Holdings (NYSE American: SCPX) lobt das US-Repräsentantenhaus für die Verabschiedung des BIOSECURE Act mit starker parteiübergreifender Unterstützung (Abstimmung 306-81). Diese Gesetzgebung zielt darauf ab, die pharmazeutische Lieferkette Amerikas zu sichern, die nationale Biosicherheit zu stärken und die Vorbereitung auf öffentliche Gesundheitsnotfälle zu verbessern. Das Gesetz schränkt von der US-Regierung finanzierte Arzneimittelentwickler ein, Verträge mit ausgewählten in China ansässigen Biomanufacturing-Unternehmen abzuschließen, was potenziell die Nachfrage nach Inlandsproduktionskapazitäten erhöhen könnte.
Der CEO von Scorpius, Jeff Wolf, erwartet bedeutende Möglichkeiten zur Expansion der Projektpipeline des Unternehmens infolge dieser Gesetzgebung. Als in den USA ansässige integrierte Vertragsentwicklungs- und Fertigungsorganisation (CDMO) ist Scorpius positioniert, um Biopharmazeutika zu unterstützen, die sich mit diesen Veränderungen auseinandersetzen, mit seiner modernen Expertise und modernen Einrichtungen.
- Potential increase in demand for Scorpius' domestic biomanufacturing services due to the BIOSECURE Act
- Strong bipartisan support for the Act (306-81 vote) increases likelihood of Senate passage
- Scorpius' U.S.-based facilities and expertise position it favorably to benefit from the legislation
- The BIOSECURE Act still needs to pass the U.S. Senate to become law
- Increased competition from other domestic CDMOs as demand shifts to U.S.-based manufacturers
Insights
The passage of the BIOSECURE Act marks a significant shift in U.S. pharmaceutical policy. This legislation aims to reduce dependence on foreign biomanufacturing, particularly from China, for government-funded drug development. The Act's implications are far-reaching:
- Enhanced national security through domestic drug production
- Potential boost for U.S.-based CDMOs like Scorpius
- Increased costs for pharmaceutical companies transitioning to domestic suppliers
While the Act promises improved biosecurity, it may lead to short-term supply chain disruptions and higher drug prices. Long-term, it could stimulate domestic biomanufacturing innovation and create jobs. Investors should monitor how quickly the industry adapts and whether the Senate passes the bill.
The BIOSECURE Act represents a paradigm shift for the biotech industry. For companies like Scorpius, this legislation opens up substantial growth opportunities in the domestic CDMO market. Key points to consider:
- Increased demand for U.S.-based biomanufacturing capabilities
- Potential for expanded government contracts and partnerships
- Accelerated investment in domestic biotech infrastructure
However, the transition won't be without challenges. Smaller biotech firms may face increased costs and potential delays in drug development. Investors should look for companies with established U.S. manufacturing presence and strong government relationships to capitalize on this shift.
The BIOSECURE Act could be a game-changer for Scorpius Holdings and similar U.S.-based CDMOs. While specific financial projections aren't provided, several factors suggest positive implications:
- Potential for increased revenue streams from government-backed projects
- Likely expansion of client base as pharma companies seek domestic partners
- Possible need for capital investment to scale operations rapidly
Investors should watch for upcoming quarterly reports to gauge the Act's impact on Scorpius's project pipeline and revenue growth. The company's ability to quickly scale operations and secure new contracts will be important in capitalizing on this opportunity. Keep an eye on profit margins as competition in the domestic CDMO space may intensify.
Scorpius Poised to Support Expanded U.S. Government-Backed Project Pipeline as U.S. Drugmakers Seek to Shift to Domestic Suppliers Amid Industry-Changing Legislation
DURHAM, N.C., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization ("CDMO"), today commended the U.S. House of Representatives on the passage of the BIOSECURE Act (the “Act”), a pivotal piece of legislation passed with strong bipartisan support following a 306-81 vote earlier this week.
The Act is designed to ensure the security of America’s pharmaceutical supply chain, strengthen national biosecurity, and improve overall preparedness for future public health emergencies. The Act now moves to the U.S. Senate, representing a critical step in bolstering the country's biotechnology and biomanufacturing infrastructure to ensure long-term public health resilience in the face of challenges from America’s adversaries.
The BIOSECURE Act aims to secure the U.S. pharmaceutical supply chain by restricting U.S. Government-funded drug developers from contracting with select China-based biomanufacturing companies of concern for production of their drugs. The Act is designed to reduce U.S. dependence on foreign owned and operated biomanufacturing supply chains which will enhance national security and generate more on-shoring jobs focused on improving robustness in us health care systems.
Jeff Wolf, CEO of Scorpius, stated, “We owe a debt of gratitude to Reps. Wenstrup, Krishnamoorthi, and Moolenaar for their leadership in advancing the BIOSECURE Act, that enhances America’s health security and protects our supply chain from foreign threats. The BIOSECURE Act enables Scorpius to leverage our expertise and resources to support America’s biopharmaceutical companies that collaborate with the U.S. Government in the production of their drugs. We believe that our cutting-edge biomanufacturing expertise, purpose-built capabilities, combined with our modern US-based production facilities gives us a distinct advantage in addressing the changing demands of biopharmaceutical companies and government agencies tasked with managing biological threats. We are fully dedicated to fast-tracking the development of medical countermeasures and delivering scalable, forward-thinking solutions that protect public health and reinforce national security.
"The BIOSECURE Act enhances our ability to deliver impactful, timely responses in critical moments of need. With the passage of the BIOSECURE Act, we foresee significant opportunities to further expand our already robust pipeline of projects. As a result of this legislation, we expect a growing demand for domestic production capabilities and biomanufacturing services, positioning Scorpius as a key partner for pharmaceutical companies navigating these changes,” concluded Mr. Wolf.
Scorpius Holdings, Inc.
Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements such as the BIOSECURE Act representing a pivotal opportunity for Scorpius to leverage its expertise and resources to support America’s biopharmaceutical companies who are responding to indications of interest to the U.S. Government in the production of their drugs; the Company’s cutting-edge biomanufacturing expertise, purpose-built capabilities, combined with its modern US-based production facilities, giving it a distinct advantage in addressing the changing demands of biopharmaceutical companies and government agencies tasked with managing biological threats; the legislation enhancing the Company’s ability to deliver impactful, timely responses in critical moments of need; the passage of the BIOSECURE Act resulting in significant opportunities to further expand the Company’s already robust pipeline of projects; positioning Scorpius as a key partner for pharmaceutical companies navigating the changes from the expected growing demand for domestic production capabilities and biomanufacturing services; and the Company’s advanced facilities and expertise making it well-equipped to meet the increasing need for reliable, secure supply chains in the U.S., further strengthening the Company’s position in the market. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of the Company to derive the anticipated benefits form the BIOSECURE Act; the Company’s ability to expand its large molecule biomanufacturing CDMO services, attract new customers, profit from its pipeline and continue to grow revenue; the ability to capture a meaningful market share; the ability to generate meaningful cash flow and become cash flow positive; the Company’s financing needs, its cash balance being sufficient to sustain operations and its ability to raise capital when needed, the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing regulatory requirements, regulatory limitations relating to the Company’s ability to successfully promote its services and compete as a pure- play CDMO, and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, subsequent quarterly reports on Form 10-Qs and any other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
ir@scorpiusbiologics.com
FAQ
What is the BIOSECURE Act and how does it affect Scorpius Holdings (SCPX)?
How did the U.S. House of Representatives vote on the BIOSECURE Act?
What opportunities does Scorpius Holdings (SCPX) anticipate from the BIOSECURE Act?
What services does Scorpius Holdings (SCPX) offer as a CDMO?
